AGM
IBRX icon

Alpine Global Management’s ImmunityBio IBRX Stock Holding History

Alpine Global Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,753
Closed -$56K – 382
2025
Q3 		$56K Buy
+22,753
New +$58.6K 0.01% 167
2024
Q3 		– Sell
-12,734
Closed -$80.5K – 286
2024
Q2 		$80.5K Buy
+12,734
New +$84K 0.01% 434
2022
Q1 		– Sell
-14,805
Closed -$90K – 574
2021
Q4 		$90K Buy
+14,805
New +$111K 0.01% 677
2020
Q2 		– Sell
-11,056
Closed -$32K – 367
2020
Q1 		$32K Sell
11,056
-2,418
-18% -$12.1K 0.01% 192
2019
Q4 		$51K Buy
+13,474
New +$22.9K 0.01% 390

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Alpine Global Management's IBRX Position: Q4 2025 in Review

Alpine Global Management sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 22,753 shares — an estimated $56K sold.

Alpine Global Management first reported a position in IBRX in Q4 2019 and held it in 5 quarters. The position peaked at $90K in Q4 2021. 276 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Alpine Global Management reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Alpine Global Management sold 22,753 ImmunityBio shares in Q4 2025, an estimated $56K.
  • Alpine Global Management first reported a position in ImmunityBio in Q4 2019 and held it in 5 quarters.
  • Alpine Global Management's ImmunityBio position peaked at $90K in Q4 2021.
  • 276 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Alpine Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.